T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Park National Corp
PRK
$3.75B
| $2.63M | ﹤0.01% |
17,307
-818
| -5% | -$129K |
|
1627
ScottsMiracle-Gro
SMG
$3.57B
| $2.63M | ﹤0.01% |
45,032
+2,473
| +6% | +$139K |
|
1628
Supernus Pharmaceuticals
SUPN
$2.78B
| $2.62M | ﹤0.01% |
52,786
+2,880
| +6% | +$140K |
|
1629
Privia Health
PRVA
$2.84B
| $2.62M | ﹤0.01% |
110,564
+9,111
| +9% | +$222K |
|
1630
Liberty Media Series A
FWONA
$24.1B
| $2.61M | ﹤0.01% |
29,232
+899
| +3% | +$80.7K |
|
1631
Remitly
RELY
$5.5B
| $2.61M | ﹤0.01% |
189,245
-3,652,229
| -95% | -$53.1M |
|
1632
HUB Group
HUBG
$2.51B
| $2.59M | ﹤0.01% |
60,829
+1,927
| +3% | +$73.3K |
|
1633
Mercury Insurance
MCY
$5.82B
| $2.59M | ﹤0.01% |
27,555
+862
| +3% | +$74.8K |
|
1634
SSR Mining
SSRM
$6.59B
| $2.58M | ﹤0.01% |
117,621
+5,747
| +5% | +$128K |
|
1635
NCR Atleos
NATL
$3.47B
| $2.58M | ﹤0.01% |
67,616
+4,235
| +7% | +$159K |
|
1636
Metropolitan Bank Holding Corp
MCB
$1.16B
| $2.56M | ﹤0.01% |
33,572
-20,358
| -38% | -$1.51M |
|
1637
Victory Capital Holdings
VCTR
$7.29B
| $2.55M | ﹤0.01% |
40,445
+1,709
| +4% | +$109K |
|
|
LIF
1638
Life360
LIF
$4.19B
| $2.55M | ﹤0.01% |
39,766
-94,729
| -70% | -$7.87M |
|
1639
Karat Packaging
KRT
$936M
| $2.55M | ﹤0.01% |
112,795
+8,101
| +8% | +$188K |
|
1640
Ubiquiti
UI
$34.9B
| $2.55M | ﹤0.01% |
4,600
+453
| +11% | +$287K |
|
1641
First Merchants
FRME
$2.74B
| $2.54M | ﹤0.01% |
67,787
+1,104
| +2% | +$40.9K |
|
1642
Minerals Technologies
MTX
$2.26B
| $2.53M | ﹤0.01% |
41,570
+6,347
| +18% | +$376K |
|
1643
Western Union
WU
$2.3B
| $2.51M | ﹤0.01% |
269,435
+11,943
| +5% | +$105K |
|
1644
NBT Bancorp
NBTB
$2.79B
| $2.51M | ﹤0.01% |
60,400
+5,142
| +9% | +$214K |
|
1645
DigitalBridge
DBRG
$2.95B
| $2.51M | ﹤0.01% |
163,366
+13,413
| +9% | +$161K |
|
1646
Insight Enterprises
NSIT
$4.56B
| $2.5M | ﹤0.01% |
30,713
+4,059
| +15% | +$381K |
|
|
CURB
1647
Curbline Properties
CURB
$3.48B
| $2.49M | ﹤0.01% |
107,389
-1,036,655
| -91% | -$24.2M |
|
1648
Ingevity
NGVT
$2.59B
| $2.48M | ﹤0.01% |
41,841
+1,467
| +4% | +$79.6K |
|
1649
Standex International
SXI
$4B
| $2.47M | ﹤0.01% |
11,361
+982
| +9% | +$228K |
|
1650
Kulicke & Soffa
KLIC
$5.07B
| $2.46M | ﹤0.01% |
54,013
+2,706
| +5% | +$114K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.